49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma
Ali Hajj Ali, Liliana Ascione, Rashad Nawfal, Wassim Daoud Khatoun, Pablo Barrios, Marc Machaalani, Razane El Hajj Chehade, Jad El Masri, Mustafa Saleh, Marc Eid, Elio Ibrahim, Gaelle Nafeh, Tarek Baroud, Sara El Sarout, Bradley A McGregor, Toni K Choueiri · 2026
Read 49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma by Ali Hajj Ali, Liliana Ascione, Rashad Nawfal, Wassim Daoud Khatoun, Pablo Barrios, Marc Machaalani, Razane El Hajj Chehade, Jad El Masri, Mustafa Saleh, Marc Eid, Elio Ibrahim, Gaelle Nafeh, Tarek Baroud, Sara El Sarout, Bradley A McGregor, Toni K Choueiri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13535414.txt.
Description
Ali Hajj Ali and co-authors ask in 2026 if other illnesses change how well a kidney cancer drug works. The drug, belzutifan, helps patients whose advanced cancer was treated before with immune and vessel drugs. Yet people with many other health problems are often left out of trials, so its real-world fit is unclear.
The team gathered records for patients treated with the drug after first-line care. They scored each person's burden of other illness and weighed it against tumor response and side effects. If burden blunts the drug or raises harm, doctors need that warning. If not, more patients could be offered it with confidence.
Catalog record
| CREATOR | Ali Hajj Ali, Liliana Ascione, Rashad Nawfal, Wassim Daoud Khatoun, Pablo Barrios, Marc Machaalani, Razane El Hajj Chehade, Jad El Masri, Mustafa Saleh, Marc Eid, Elio Ibrahim, Gaelle Nafeh, Tarek Baroud, Sara El Sarout, Bradley A McGregor, Toni K Choueiri |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |